Devices industry still struggling to provide robust clinical evidence
This article was originally published in Clinica
The medical devices industry is still struggling to provide adequate safety and efficacy data on the clinical performance of its products, and is still not providing a sufficient evidence base on which purchasers can base decisions about the value of its products. That is the view of chief executive of the Medicines and Healthcare products Regulatory Agency, Professor Kent Woods.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.